Rhythm Pharmaceuticals (RYTM) Cash from Investing Activities (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Cash from Investing Activities data on file, last reported at $57.1 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $57.1 million, up 129.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$104.9 million (down 96.43% YoY), and the FY2025 annual result was -$137.2 million, down 184.71% from the prior year.
• Cash from Investing Activities advanced to $57.1 million in Q1 2026 per RYTM's latest filing, from $30.3 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $72.5 million in Q1 2022 and troughed at -$246.3 million in Q3 2025.
• A 5-year average of -$6.2 million and a median of $22.6 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities plunged 662.57% in 2022, then soared 731.1% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$40.8 million in 2022, then jumped by 155.52% to $22.6 million in 2023, then slipped by 6.55% to $21.2 million in 2024, then surged by 43.44% to $30.3 million in 2025, then jumped by 88.0% to $57.1 million in 2026.
• Business Quant data shows RYTM's Cash from Investing Activities at $57.1 million in Q1 2026, $30.3 million in Q4 2025, and -$246.3 million in Q3 2025.